Search - tctmd.com

Displaying 21 - 40 of 101

Sort: Relevancy | Date

Direct Temsirolimus Delivery Shows Promise in BTK: Phase II Study

News Conference News TCT 2020

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

Caitlin E. Cox

October 18, 2020

News Conference News TCT 2020

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

L.A. McKeown

October 18, 2020

News Daily News

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

L.A. McKeown

September 17, 2020

News Daily News

ILLUMENATE EU: No Higher Paclitaxel-Related Deaths as Talk Turns to Patency

L.A. McKeown

July 02, 2020

News Conference News LINC 2020

Algorithm Aims to Help Operators Pair Laser Settings With PAD Lesion Type

L.A. McKeown

February 06, 2020

News Conference News LINC 2020

DCBs Show Consistent Long-term Benefits in Complex Fem-Pop Patient Subsets

L.A. McKeown

January 30, 2020

News Conference News LINC 2020

Lutonix BTK Studies: Below-the-Knee Challenges Linger

L.A. McKeown

January 29, 2020

News Conference News LINC 2020

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

L.A. McKeown

January 28, 2020

News Daily News

Paclitaxel DCBs Now Implicated in Death, Amputation in Below-the-Knee CLI

L.A. McKeown

January 15, 2020

News Conference News VIVA 2019

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

L.A. McKeown

November 06, 2019

News Conference News VIVA 2019

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

L.A. McKeown

November 05, 2019

News Daily News

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

Caitlin E. Cox

July 11, 2019

News Daily News

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

L.A. McKeown

June 20, 2019

News Conference News EuroPCR 2019

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

L.A. McKeown

May 23, 2019

News Conference News CRT 2019

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

Yael L. Maxwell

March 14, 2019

News Conference News CRT 2019

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

L.A. McKeown

March 06, 2019

News Daily News

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

L.A. McKeown

March 01, 2019

News Conference News ISET 2019

PVI in Symptomatic Lower-Extremity PAD Offers Multiple Benefits, Even 2.5 Years Later

Caitlin E. Cox

February 07, 2019

News Conference News ISET 2019

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

Caitlin E. Cox

January 30, 2019

News Conference News VIVA 2018

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

L.A. McKeown

November 13, 2018

Advertisement

Direct Temsirolimus Delivery Promising in BTK: TANGO Phase II Study

IN.PACT BTK Provides Renewed Hope for Attacking CLI With DCBs

Registry Supports Paclitaxel DCBs in CLI Patients to 2 Years

ILLUMENATE EU: No Higher Paclitaxel-Related Deaths as Talk Turns to Patency

Algorithm Aims to Help Operators Pair Laser Settings With PAD Lesion Type

DCBs Show Consistent Long-term Benefits in Complex Fem-Pop Patient Subsets

Lutonix BTK Studies: Below-the-Knee Challenges Linger

COMPARE: Similar Efficacy and Safety for Paclitaxel Balloons Regardless of Dose

Paclitaxel DCBs Now Implicated in Death, Amputation in Below-the-Knee CLI

Hope for Bioresorbable Vascular Scaffolds in Peripheral Disease Below the Knee?

IN.PACT Global Registry Shows Continued Safety, Efficacy at 4 Years for Paclitaxel DCB

DCB Match DES Through 1 Year in Femoropopliteal Lesions, DRASTICO Affirms

FDA Panel Talks Labeling, Urges Cooperation for Paclitaxel Mortality Signal in PAD

EFFPAC: Novel Paclitaxel DCB for PAD Demonstrates Efficacy With No Mortality Signal

SAFE-DCB Demonstrates Consistent Efficacy at 1 Year in Real-world Femoropopliteal Disease Patients

Acknowledgment of Safety Signal for Paclitaxel Devices in PAD May Mark Sea Change in Controversy

A Day of Data: Signal of Mortality Increase With Paclitaxel Devices in PAD Continues to Vex

PVI in Symptomatic Lower-Extremity PAD Offers Multiple Benefits, Even 2.5 Years Later

Eluvia Sustains Lead Over Zilver PTX in Patients With Diabetes: IMPERIAL Subanalysis

No Gender Difference in Patency Rates 1 Year After DCB for PAD: ILLUMENATE Substudy

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content